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Abstract
Background: Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus (EBV)-associated, highly aggressive
lymphoma. Treatment outcome remains sub-optimal, especially for advanced-stage or relapsed diseases. Programmed
cell death receptor 1 (PD-1) and PD ligand 1 (PD-L1) have become promising therapeutic targets for various malignancies,
but their role in the pathogenesis and their interactions with EBV in NKTCL remains to be investigated.
Methods: Expression of PD-L1 was measured in NK-92 (EBV-negative) and SNK-6 (EBV-positive) cells by western blot,
quantitative real-time PCR and enzyme-linked immunosorbent assay, and flow cytometry, respectively. Latent membrane
protein 1 (LMP1)-harboring lentiviral vectors were transfected into NK-92 cells to examine the correlation between LMP1
and PD-L1 expression. Proteins in the downstream pathways of LMP1 signaling were measured in NK-92 cells transfected
with LMP1-harboring or negative control vectors as well as in SNK-6 cells. PD-L1 expression on tumor specimens and
serum concentration of soluble PD-L1 were collected in a retrospective cohort of patients with Ann Arbor stage I~II
NKTCL, and their prognostic significance were analyzed.
Results: Expression of PD-L1 was significantly higher in SNK-6 cells than in NK-92 cells, at both protein and mRNA levels.
Expression of PD-L1 was remarkably upregulated in NK-92 cells transfected with LMP1-harboring lentiviral
vectors compared with those transfected with negative control vectors. Proteins in the MAPK/NF-κB pathway
were upregulated in LMP1-expressing NK-92 cells compared with the negative control. Selective inhibitors of
those proteins induced significant downregulation of PD-L1 expression in LMP1-expressing NK-92 cells as well
as in SNK-6 cells. Patients with a high concentration of serum soluble PD-L1 (≥3.4 ng/ml) or with a high
percentage of PD-L1 expression in tumor specimens (≥38 %) exhibited significantly lower response rate to
treatment and remarkably worse survival, compared with their counterparts. A high concentration of serum
soluble PD-L1 and a high percentage of PD-L1 expression in tumor specimens were independent adverse
prognostic factors among patients with stage I~II NKTCL.
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Conclusions: PD-L1 expression positively correlated LMP1 expression in NKTCL, which was probably mediated
by the MAPK/NF-κB pathway. PD-L1 expression in serum and tumor tissues has significant prognostic value for
early-stage NKTCL.
Keywords: Natural killer/T-cell lymphoma, Latent membrane protein 1, Epstein–Barr virus, Programmed cell
death receptor 1
Background
Natural killer/T-cell lymphoma (NKTCL) is a distinct and
aggressive clinicopathologic entity in the World Health
Organization (WHO) classification of hematopoietic and
lymphoid malignancies [1–3]. NKTCL is rare in North
America and Europe but is more common in East Asia
and South America [4]. This disease predominates in
young males, and most cases originate from the nasal cavity
[1, 2, 4]. No standard treatment strategy has been estab-
lished due to the rarity of NKTCL. Radiotherapy (RT) has
yielded curative effects for early-stage disease [5–7].
Anthracycline-based chemotherapeutic regimens have
shown disappointing efficacy, probably due to the overex-
pression of multidrug-resistant genes [8–10]. Novel regi-
mens containing L-asparaginase or pegaspargase have
elicited promising responses [11–13]. However, the out-
come of NKTCL remains sub-optimal, especially for
advanced-stage or relapsed diseases [14, 15]. Therefore, it is
in urgent need to identify novel therapeutic targets and cor-
responding agents.
Tumor immune escape is an emerging hallmark of
cancer. Programmed cell death receptor 1 (PD-1) and
PD ligand 1 (PD-L1) are important immune checkpoint
molecules involved in T cell-mediated immune response
and are key regulators of tumor immune escape [16–18].
Aberrant expression of PD-1/PD-L1 on tumor cells or
tumor-infiltrating lymphocytes has conferred adverse
prognostic impact in multiple solid and hematopoietic
malignancies [19–23]. Blockade of the PD-1/PD-L1 in-
teractions with monoclonal antibodies has achieved en-
couraging efficacy and has been approved by the US
Food and Drug Administration (FDA) in many malig-
nancies [24–27]. Expression of PD-L1 on tumor cells
has been reported in patients with NKTCL, which may
be a potential therapeutic target in the future [28, 29].
However, the role of PD-1/PD-L1 in the pathogenesis of
NKTCL remains poorly understood.
There is a close correlation between Epstein–Barr
virus (EBV) infection and NKTCL. Almost all cases of
NKTCL exhibited a positive result of EBV-encoded RNA
in situ hybridization in tumor samples. Additionally,
pre- and post-treatment levels of circulating EBV DNA
had significant prognostic implications for NKTCL pa-
tients [30–33]. In previous studies, expression of PD-1/
PD-L1 could be upregulated by EBV infection in various
malignancies [34–37], and blockade of PD-1/PD-L1 in-
teractions successfully inhibited EBV-induced lymphoma
growth in a mouse model [38], suggesting a possible
interaction between EBV and PD-1/PD-L1 pathway in
tumor immunology. Whether such an interaction exists
in NKTCL, a typical EBV-associated malignancy, re-
mains to be explored. In the present study, we aim to
explore the interaction between EBV infection and PD-
L1 expression in NKTCL cell lines and the clinical sig-
nificance of PD-L1 expression in NKTCL patients.
Methods
Cell lines and culture
The SNK-6 and NK-92 cells were routinely kept in Sun
Yat-sen University Cancer Center (SYSUCC) and were in-
cubated in a humidified incubator with 5 % CO2 at 37 °C.
The SNK-6 cell line was cultured in RPMI-1640 (Gibco,
USA) medium containing 2 mmol/l glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin, supplemented with
1000 U/ml interleukin (IL)-2 (Sigma-Aldrich, USA) and
10 % human AB serum (Gemini Bioproducts, Woodland,
CA, USA). The NK-92 cells were maintained in α-MEM
(Life Technologies, Karlsruhe, Germany) containing 20 %
FBS (Gibco, USA), 2 mM L-glutamate, 100 mg/ml penicil-
lin, and 100 mg/ml streptomycin (Life Technologies) and
supplemented with 10 ng/ml IL-2 (Sigma-Aldrich, USA).
Western blot analysis
Cells were washed with ice-cold PBS and were sus-
pended in radioimmunoprecipitation assay (RIPA) lysis
buffer (Biyuntian Biotech, Shanghai, China) containing
1 % phenylmethylsulfonyl. After centrifugation at
14,000 rpm for 10 min at 4 °C, the protein content of
supernatant was determined using the Pierce™ BCA Pro-
tein Assay Kit (Thermo Scientific, Rockford, IL, USA).
Aliquots (20 μg protein per lane) were separated by
12 % sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene
fluoride (PVDF) membranes (Millipore, Billerica, MA,
USA). The membranes were exposed to primary anti-
bodies and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (1: 2000, Abcam) at room temperature for
1 h, followed by labeling with horseradish peroxidase-
conjugated goat anti-rabbit IgG (1: 20,000, Boster,
Wuhan, China) for 40 min at room temperature. Signals
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were detected with enhanced chemiluminescence plus
reagents (Amersham Pharmacia, Piscataway, NJ, USA).
GAPDH was used as the internal control. The following
primary antibodies were used: PD-L1, B-Raf, p-B-Raf,
p38, p-p38, ERK, pERK (Abcam, Shanghai, China), latent
membrane protein 1 (LMP1), JNK, pJNK (Santa Cruz,
Shanghai, China), and p65 (Boster, Wuhan, China).
Quantitative real-time PCR (qRT-PCR) analysis
In order to quantify PD-L1 and LMP1 mRNA, total RNA
was isolated from SNK-6 and NK-92 cells using TRIZOL
Reagent (Invitrogen, USA) according to the instruction
manual. One microgram of the total RNA was reversely
transcribed into cDNA using Bestar™ qPCR RT Kit (DBI
Bioscience, China). The qRT-PCR reaction was prepared
in a total volume of 20 μl containing 10 μl DBI Bestar®
SybrGreen qPCR Master Mix (DBI Bioscience, China),
cDNA derived from 0.2 μg of input RNA, 5 pM each
primer, and 7 μl double-distilled H2O. The PCR was
run on Stratagene Mx3000P Real-Time PCR system
(Agilent Technologies, USA). The fluorescent quantity
PCR conditions were as follows: pre-denaturation at
95 °C for 2 min, followed by 40 cycles of 94 °C for
20 s, 58 °C for 20 s, and 72 °C for 30 s. Primers were
as follows: PD-L1 forward 5′-GAACTACCTCTGGCA
CATCCT-3′, PD-L1 reverse 5′-CACATCCATCATT
CTCCCTTT-3′; LMP1 forward 5′-CAACAACGGCA
AGACTCCC-3′, LMP1 reverse 5′-CCTCAAAGA
AGCCACCCTC-3′. Each reaction was replicated three
times. The fold changes in cDNA relative to the GAPDH
endogenous control were calculated using the 2−ΔΔCt
method [39].
Measurement of soluble PD-L1 in cell culture supernatant
The cell mixture was centrifuged at 1500 rpm for 5 min.
The supernatant was collected and determined for the
concentration of soluble PD-L1 using a sandwich
enzyme-linked immunosorbent assay (ELISA) kit
(PDCD1LG1 ELISA kit, Cloud-Clone Corp., Wuhan,
China) according to the manufacturer’s instructions.
Flow cytometry analysis
Cells were labeled with anti-PD-L1 antibody (Alexa Fluor
647; Abcam, Shanghai, China) and then were assayed by
flow cytometry using the Cytomics FC 500MPL cytometer.
Data were collected and analyzed with the CXP version 2.2
software (Beckman Coulter Inc.).
Construction of a LMP1-expressing NK-92 cell line
The LMP1-expressing lentivirus vector, LV5-LMP1, was
constructed by the insertion of a full-length LMP1 cDNA
into LV5 vector (GenePharma Co. Ltd., China) at NotI and
BamHI sites. The LV5-LMP1 vector and LV5 control
vector (LV5-NC) were, respectively, cotransfected with
packaging vectors pGag/Pol, pRev, and pVSV-G
(GenePharma Co. Ltd., China) into HEK-293T cells using
Lipofectamine 2000 Transfection Reagent (Beyotime,
Shanghai, China). After culturing for 72 h, the supernatants
of the transfected cells were harvested. The lentiviral titers
were determined by flow cytometric analysis for green
fluorescence protein (GFP) expressed by viral vectors. 1 ×
105/well NK-92 cells were infected with LV5-LMP1 and
LV5-NC vectors, respectively, at a multiplicity of infection
(MOI) of 300. After culturing for 48 h, western blot and
ELISA were performed to determine the expression of pro-
teins in NK-92 cells infected by LV5-LMP1 and LV5-NC,
respectively.
Measurement of serum soluble PD-L1 in NKTCL patients
Serum samples were collected before treatment from 77
patients with newly diagnosed NKTCL between 2008
and 2015 at SYSUCC and from 15 healthy volunteers.
Serum was collected from the whole blood by centrifu-
ging at 4000×g and stored at −80 °C. The level of soluble
PD-L1 was determined using a sandwich ELISA kit
(PDCD1LG1 ELISA kit, Cloud-Clone Corp., Wuhan,
China) as per the manufacturer’s protocol.
Immunohistochemical analysis of PD-L1 in biopsy
specimen from NKTCL patients
Paraffin-embedded specimens were collected before treat-
ment from the same NKTCL patients described above.
Four-micrometer-thick sections were deparaffinized, rehy-
drated, and quenched. Immunohistochemical staining was
performed using an anti-PD-L1 rabbit polyclonal antibody
(1:50 dilution, Abcam, Cambridge, UK) and a two-stage im-
munohistochemical kit (ChemMate™ Envision Detection
Kit, Peroxidase/DAB, Dako, Glostrup, Denmark) according
to the manufacturer’s instructions. The number of all
tumor cells and those with membrane PD-L1 staining were
calculated manually under high magnification (×200) using
Image Pro Plus 6.0 software (Media Cybernetics, Maryland,
USA). Seven fields were calculated for each individual spe-
cimen to determine the percentage of tumor cells with
membrane staining among all tumor cells. In order to
minimize intra-tumor heterogeneity, two fields with the
highest and lowest percentages were eliminated, and the
average percentage of the remaining five fields was used to
represent the level of PD-L1 expression for an individual.
Clinical data and treatment
Seventy-seven patients with previously untreated
NKTCL diagnosed at SYSUCC between 2008 and 2015
were enrolled in this study. The diagnosis was based on
the WHO classification of hematopoietic and lymphoid
tumors, and all patients had positive results for EBV-
encoded RNA (EBER) in situ hybridization (ISH) [1, 2].
The clinical characteristics and treatment modalities are
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summarized in Table 1. All patients had Ann Arbor
stage I or II disease. The International Prognostic Index
(IPI) and the natural killer/T-cell lymphoma prognostic
index (NKPI) were calculated for risk stratification
[40, 41]. The majority of patients were categorized into
the low-risk IPI (0–1, 89.6 %) or NKPI (0–1, 72.7 %) group.
All patients received induction chemotherapy followed by
consolidative radiotherapy (RT) as their primary treatment.
66.2 % of the patients received GELOX (gemcitabine, L-
asparaginase, and oxaliplatin) and 33.8 % received CHOP-L
(cyclophosphamide, doxorubicin, vincristine, prednisone,
and L-asparaginase) as induction chemotherapeutic regi-
men in dosages as previously reported [42]. Complete re-
mission (CR) was achieved after primary therapy in 76.6 %
of the patients. The median follow-up period for this cohort
was 38.0 (9.4–79.0) months.
Statistical analysis
Continuous variables were compared using a two-tailed
Student’s t test, and categorical variables were compared
using the chi-square test or the Fisher’s exact test. Over-
all survival (OS) was measured from the date of diagno-
sis to the date of death or the most recent follow-up.
Progression-free survival (PFS) was measured from the
date of diagnosis to the date of disease progression,
death, or the most recent follow-up. Survival data were
calculated with the Kaplan-Meier method and compared
using the log-rank test. Variables with statistical signifi-
cance in univariate analysis were included in the multi-
variate analysis using a stepwise forward Cox regression
model. Optimal cut-off values of serum and histological
PD-L1 levels for predicting survival were determined
using the receiver operating characteristics (ROC) curve
analysis. The Spearman correlation test was used to ex-
plore the correlation between the serum and histological
PD-L1 levels. Differences were considered statistically
significant with a two-sided P value of <0.05. The statis-
tical analysis was performed using SPSS version 17.0
software (SPSS, Inc., Chicago, IL, USA).
Results
PD-L1 expression was higher in EBV+NKTCL cell line
Western blot, ELISA, flow cytometry, and qRT-PCR
were performed to determine protein and mRNA levels
of PD-L1, respectively, in two cell lines: the human NK
cell line NK-92 (EBV-negative) and the NKTCL cell line
SNK-6 (EBV-positive). The protein level of PD-L1 was
remarkably higher in SNK-6 cell line than that in NK-92
cells (Fig. 1a). Consistently, the relative expression level
of PD-L1 mRNA in SNK-6 cells was also significantly
Table 1 The clinical characteristics and treatment modalities of patients with NK/T-cell lymphoma
Parameters Total n (%) PD-L1 < 3.4 ng/ml n (%) PD-L1≥ 3.4 ng/ml n (%) P value PD-L1 < 38 % n (%) PD-L1≥ 38 % n (%) P value
Overall 77 (100) 51 (100) 26 (100) – 51 (100) 26 (100) –
Male gender 42 (54.5) 23 (45.1) 19 (73.1) 0.020 26 (51.0) 16 (61.5) 0.379
Age > 60 years 11 (14.3) 10 (19.6) 1 (3.8) 0.087 9 (17.6) 2 (7.7) 0.316
ECOG score≥ 2 4 (5.2) 1 (2.0) 3 (11.5) 0.109 2 (3.9) 2 (7.7) 0.600
Ann Arbor stage
I 41 (53.2) 31 (60.8) 10 (38.5) 0.063 30 (58.8) 11 (42.3) 0.170
II 36 (46.8) 20 (39.2) 16 (61.5) 21 (41.2) 15 (57.7)
B symptoms 22 (28.6) 12 (23.5) 10 (38.5) 0.170 13 (25.5) 9 (34.6) 0.433
LDH > 245 U/L 18 (23.4) 10 (19.6) 8 (30.8) 0.274 10 (19.6) 8 (30.8)
IPI score
0–1 69 (89.6) 47 (92.2) 22 (84.6) 0.432 47 (92.2) 22 (84.6) 0.432
2 8 (10.4) 4 (7.8) 4 (15.4) 4 (7.8) 4 (15.4)
NKPI score
0–1 56 (72.7) 39 (76.5) 17 (65.4) 0.302 38 (74.5) 18 (69.2) 0.623
2–3 21 (27.3) 12 (23.5) 9 (34.6) 13 (25.5) 8 (30.8)
Chemotherapy regimen
GELOX 51 (66.2) 34 (66.7) 17 (65.4) 0.910 35 (68.6) 16 (61.5) 0.534
CHOP-L 26 (33.8) 17 (33.3) 9 (34.6) 16 (31.4) 10 (38.5)
Treatment response
CR 59 (76.6) 43 (84.3) 16 (61.5) 0.026 43 (84.3) 16 (61.5) 0.026
Non-CR 18 (23.4) 8 (15.7) 10 (38.5) 8 (15.7) 10 (38.5)
Abbreviations: CR complete remission, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, NKPI natural
killer/T-cell lymphoma prognostic index
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higher than that in NK-92 cells (Fig. 1b, P < 0.05). ELISA
of cell culture supernatants found a remarkably higher
level of soluble PD-L1 produced by SNK-6 cells than
NK-92 cells (Fig. 1c, P < 0.05). Additionally, expression
of PD-L1 on cell surface was much higher in SNK-6 cells
(Fig. 1e) than in NK-92 cells (Fig. 1d).
LMP1 upregulated PD-L1 expression in NK-92 cells
To investigate whether LMP1 expression in NK-92
cells was associated with upregulated PD-L1 level, we
constructed a novel LMP1-expressing NK-92 cell line
using a LV5-LMP1 lentiviral vector. Good infection ef-
ficiency of both LV5-LMP1 and LV5-NC vectors for
NK-92 cell lines was observed at an MOI of 300
(Fig. 2a, b). Western blot and qRT-PCR found remark-
ably higher levels of LMP1 protein (Fig. 2c) and
mRNA (Fig. 2d, P < 0.05) in NK-92 cells transfected
with LV5-LMP1 vector, compared with those trans-
fected with LV5-NC. Accordingly, remarkable upregu-
lation of both PD-L1 protein (Fig. 2c) and mRNA
(Fig. 2e, P < 0.05) was observed in the LMP1-
expressing NK-92 cells compared with the negative
control. ELISA found a significantly higher
concentration of soluble PD-L1 in cell supernatants
produced by LMP1-expressing NK-92 compared with
the negative control (Fig. 2f, P < 0.05). Additionally,
expression of PD-L1 on cell surface was much higher
in LMP1-expressing NK-92 cells (Fig. 2h) than in the
negative control (Fig. 2g).
LMP1 upregulated PD-L1 expression through
MAPK/NF-κB pathway in NK-92 cells
To explore the possible underlying mechanisms of
PD-L1 upregulation induced by LMP1, we examined
the expression of several proteins in the downstream
pathways of LMP1. As shown in Fig. 3a, p-Raf-B, p-
p38, p-JNK, p-ERK, and p65 were upregulated in the
LMP1-expressing NK-92 cells compared with the
negative control. A selective inhibitor of B-Raf
(SB590885) effectively inhibited the expression of p-
Raf-B, p-ERK, and p65 in LMP1-expressing NK-92
cells, resulting in reduced PD-L1 expression (Fig. 3b).
Additionally, PD98059 (an ERK inhibitor), SB203580
(a p38 inhibitor), and SP600125 (a JNK inhibitor)
could all effectively suppress the expression of p65 as well
as PD-L1 (Fig. 3c–e). Finally, pyrrolidine dithiocarbamate
Fig. 1 Expression of PD-L1 in NK cell line NK-92 (EBV-negative) and NKTCL cell line SNK-6 (EBV-positive). The level of a PD-L1 protein detected by
western blot, b PD-L1 mRNA detected by quantitative real-time PCR, c soluble PD-L1 protein in cell culture supernatant detected by ELISA, and d,
e PD-L1 expression on cell surface detected by flow cytometry in NK-92 and SNK-6 cell lines, respectively. **P < 0.05
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(PDTC) as a selective inhibitor of NF-κB could remarkably
reduce the expression of PD-L1 in LMP1-expressing
NK-92 cells (Fig. 3f ). These data suggested that
MAPK/NF-κB pathway may be responsible for the
LMP1-induced PD-L1 expression in human NK-92 cells. In
addition, we further repeated the experiments above in
SNK-6 cells. The results demonstrated that the effects of
lowered PD-L1 expression seen in LMP1-expressing NK-92
cell line by B-Raf, ERK, p38, JNK, or NF-κB inhibition
could also be observed in SNK-6 cells, which con-
firmed the observations made in the transfected cell
line (see Additional file 1: Figure S1).
Fig. 2 Expression of PD-L1 was upregulated by LMP1 in NK-92 cells. a, b Infection efficiency of LV5-LMP1 vector (a) and LV5 vector (LV5-NC, b) in
NK-92 cell line at a multiplicity of infection (MOI) of 100, 200, and 300, respectively. The level of c LMP1 and PD-L1 proteins detected by western
blot, d LMP1 and e PD-L1 mRNA detected by quantitative real-time PCR, f soluble PD-L1 protein in cell culture supernatant detected by ELISA,
and g, h PD-L1 expression on cell surface detected by flow cytometry in LMP1-expressing NK92 (LMP1) and negative control NK92 (NC) cell lines,
respectively. **P < 0.05
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Pretreatment histological PD-L1 expression and serum
soluble PD-L1 concentration correlated with survival in
early-stage NKTCL patients
To explore the clinical significance of PD-L1 in
NKTCL, we retrospectively examined the level of PD-
L1 expression in paraffin-embedded tissues as well as
the serum concentration of soluble PD-L1 in 77 pa-
tients with stage I–II disease. As shown in Fig. 4b, the
expression level of PD-L1 in tumor tissues positively
correlated with pretreatment serum concentration of
soluble PD-L1 (P < 0.001). Patients with NKTCL had a
significantly higher concentration of serum soluble
PD-L1 than healthy individuals (Fig. 4a, P < 0.001).
The optimal cut-off value of serum PD-L1 was 3.4 ng/ml
based on the ROC analysis (see Additional file 2:
Figure S2A). As shown in Table 1, clinical characteris-
tics were almost comparable between patients with
low (<3.4 ng/ml) or high (≥3.4 ng/ml) concentration of
serum PD-L1, except a male predominance observed in
patients with high levels of serum PD-L1 (73.1 vs. 45.1 %,
P = 0.020). After primary therapy, patients with a serum
PD-L1 ≥ 3.4 ng/ml achieved a significantly lower CR rate
than those with a serum PD-L1 < 3.4 ng/ml (61.5 vs.
84.3 %, P = 0.026, Table 1). Univariate analysis showed a
significantly inferior survival in patients with a serum
PD-L1 ≥ 3.4 ng/ml compared with those with a serum
Fig. 3 LMP1 upregulated PD-L1 expression through MAPK/NF-κB pathway in NK92 cells. a The expression level of p-Raf-B, Raf-B, p-p38, p38,
p-JNK, JNK, p-ERK, ERK, and p65 in LMP1-expressing NK92 (LMP1) and negative control NK92 (NC) cell lines. b The expression level of p-Raf-B,
Raf-B, p-p38, p38, p-JNK, JNK, p-ERK, ERK, p65, and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with
0.1 μM SB590885, a selective B-Raf inhibitor for 1 h. c The expression level of p-ERK, ERK, p65, and PD-L1 in negative control NK92 (NC) or
LMP1-expressing NK92 (LMP1) cell line treated with 20 μM PD98059, a selective ERK inhibitor for 1 h. d The expression level of p-p38, p38, p65,
and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 10 μM SB203580, a selective p38 inhibitor for 1 h.
e The expression level of p-JNK, JNK, p65, and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 20 μM
SP600125, a selective JNK inhibitor for 1 h. f The expression level of p65 and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92
(LMP1) cell line treated with 100 μM pyrrolidine dithiocarbamate (PDTC), a selective inhibitor of NF-κB for 1 h
Fig. 4 a Concentration of serum soluble PD-L1 in patients with natural killer/T-cell lymphoma (NKTCL) and healthy individuals. b Correlation
between concentration of serum soluble PD-L1 (ng/ml) and PD-L1 expression in tumor tissues (%) in patients with NKTCL
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PD-L1 < 3.4 ng/ml (3-year PFS: 23.5 vs. 81.4 %, P < 0.001,
Fig. 5a; 3-year OS: 45.3 vs. 91.0 %, P < 0.001, Fig. 5b). Serum
PD-L1 ≥ 3.4 ng/ml remained an independent adverse prog-
nostic factor for PFS and OS in multivariate analysis
(Table 2).
Representative images for PD-L1 staining in tumor
tissues are shown in Additional file 3: Figure S3. The
optimal cut-off value of histological PD-L1 expression
in tumor tissues was 38 % based on the ROC analysis
(see Additional file 2: Figure S2B). Histological PD-L1
expression was not associated with clinical characteris-
tics (Table 1). A significantly lower rate of CR after
treatment was observed in patients with PD-L1 expres-
sion of ≥38 % compared with those with PD-L1 expres-
sion of <38 % (61.5 vs. 84.3 %, P = 0.026, Table 1).
Univariate analysis showed a significantly worse sur-
vival in patients with a PD-L1 expression of ≥38 %
compared with those with a PD-L1 expression of <38 %
(3-year PFS 25.6 vs. 82.6 %, P < 0.001, Fig. 5c; 3-year
OS 46.5 vs. 90.4 %, P < 0.001, Fig. 5d). Multivariate ana-
lysis found a PD-L1 expression of ≥38 % an independ-
ent adverse prognostic factor for PFS and OS (Table 3).
Discussion
Due to the relative rarity, sub-optimal current treatment
strategies, and commonly observed chemoresistance of
NKTCL, it is urgently warranted to identify novel thera-
peutic targets. Blockade of PD-1/PD-L1 interactions has
emerged as a promising immunotherapy for cancer
patients [24–27]. Previous studies have revealed aberrant
expressions of PD-1/PD-L1 in NKTCL cell lines and tis-
sues as well as involvement of PD-1/PD-L1 in the down-
regulation of antitumor immunity, suggesting that PD-1/
PD-L1 may serve as a potential candidate for immuno-
therapy in NKTCL [28]. In the present study, we focused
on the interactions between EBV infection and PD-L1
expression in NKTCL cell lines, as well as the prognostic
impact of PD-L1 expression in NKTCL patients. Our
findings included the following: (1) PD-L1 expression
positively correlated LMP1 expression at both protein
and mRNA levels in NKTCL and NK cells; (2) PD-L1
expression was upregulated by LMP1 through the
MAPK/NF-κB pathway; and (3) the levels of PD-L1
expression on tumor tissues and the pre-treatment
concentration of serum soluble PD-L1 correlated with
the survival in early-stage NKTCL patients treated
with asparaginase-containing chemotherapy combined
with RT.
EBV plays a pivotal role in the pathogenesis of several
hematopoietic malignancies [43]. It has been reported that
overexpression of PD-L1 are commonly observed in EBV-
associated lymphomas, including classical Hodgkin’s
lymphoma, EBV-positive diffuse large B-cell lymphoma,
angioimmunoblastic T-cell lymphoma, and NKTCL [28,
29, 43, 44]. Recent in vitro studies have found that LMP1,
an EBV-encoded antigen, was able to upregulate PD-L1
expression in EBV-associated malignancies, such as
Hodgkin’s lymphoma, post-transplant lymphoproliferative
Fig. 5 a Progression-free survival (PFS) for NKTCL patients with a serum soluble PD-L1 of <3.4 and ≥3.4 ng/ml. b Overall survival (OS) for NKTCL
patients with a serum soluble PD-L1 of <3.4 and ≥3.4 ng/ml. c PFS for NKTCL patients with a histological PD-L1 expression of <38 and ≥38 %.
c OS for NKTCL patients with a histological PD-L1 expression of <38 and ≥38 %
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disorders, and nasopharyngeal carcinoma [37, 45]. In
agreement with those results, we also observed a signifi-
cant upregulation of PD-L1 expression at both protein
and mRNA levels induced by LMP1 expression in
NKTCL. First, the PD-L1 expression was much higher in
EBV-positive SNK-6 cells than in the EBV-negative NK-92
cells. Additionally, the induction of LMP1 expression in
NK-92 cells with a lentiviral vector resulted in remarkable
elevations of PD-L1 protein and mRNA. Our findings
imply that EBV infection in NKTCL probably upregulate
PD-L1 expression on tumor cells via LMP1 antigen, and
therefore induce immune tolerance.
The underlying mechanisms of PD-1/PD-L1 activation
vary between different types of cancers [45–47].
Activation of the NF-κB pathway has been observed in
NKTCL and is involved in proliferation, invasiveness,
metastasis, and chemoresistance [48, 49]. LMP1 has
been reported to contribute to the aberrant activation of
the NF-κB pathway in NKTCL [50, 51]. In addition, pre-
vious studies using genome-wide miRNA expression
profiling and exome sequencing revealed upregulation of
the MAPK signaling pathway in NKTCL, but its bio-
logical significance remains to be understood [52, 53]. In
the present study, the results showed a correlation be-
tween LMP1 and upregulation of PD-L1 expression in
NK-92 cells, and the MAPK and NF-κB pathways were
potentially involved. In line with our findings, Fang et al.
reported that LMP1 upregulated PD-L1 through STAT3,
Table 2 Univariate and multivariate analyses of prognostic factors in patients with NK/T-cell lymphoma (model 1)
Variable Progression-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
P value HR (95 % CI) P value P value HR (95 % CI) P value
Gender (female vs. male) 0.025 0.010
Age (>60 vs. ≤60 years) 0.660 0.887
ECOG score (≥2 vs. 0–1) 0.124 0.015
Stage (II vs. I) 0.001 3.06 (1.30–7.22) 0.010 0.003 4.49 (1.34–15.02) 0.015
B symptoms (yes vs. no) 0.251 0.264
LDH (elevated vs. normal) 0.020 0.001
IPI (2 vs. 0–1) 0.006 0.001 3.29 (1.13–9.57) 0.029
NKPI (2–3 vs. 0–1) 0.095 0.058
Chemotherapy (GELOX vs. CHOP-L) 0.661 0.800
Treatment response (non-CR vs. CR) 0.001 3.50 (1.53–8.01) 0.003 0.001 5.99 (1.89–18.98) 0.002
Serum PD-L1 (≥3.4 vs. <3.4 ng/ml) <0.001 4.98 (2.22–11.21) <0.001 <0.001 6.76 (2.12–21.59) 0.001
Abbreviations: CI confidence interval, CR complete remission, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, IPI International Prognostic Index,
LDH lactate dehydrogenase, NKPI natural killer/T-cell lymphoma prognostic index
Table 3 Univariate and multivariate analyses of prognostic factors in patients with NK/T-cell lymphoma (model 2)
Variable Progression-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
P value HR (95 % CI) P value P value HR (95 % CI) P value
Gender (female vs. male) 0.025 2.61 (1.13–6.02) 0.025 0.010
Age (>60 vs. ≤60 years) 0.660 0.887
ECOG score (≥2 vs. 0–1) 0.124 0.015
Stage (II vs. I) 0.001 0.003
B symptoms (yes vs. no) 0.251 0.264
LDH (elevated vs. normal) 0.020 2.26 (1.01–5.07) 0.048 0.001
IPI (2 vs. 0–1) 0.006 0.001 4.29 (1.48–12.41) 0.007
NKPI (2–3 vs. 0–1) 0.095 0.058
Chemotherapy (GELOX vs. CHOP-L) 0.661 0.800
Treatment response (non-CR vs. CR) 0.001 0.001
Histological PD-L1 (≥38 vs. <38 %) <0.001 6.76 (2.91–15.69) <0.001 <0.001 7.34 (2.36–22.86) 0.001
Abbreviations: CI confidence interval, CR complete remission, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, IPI International Prognostic Index,
LDH lactate dehydrogenase, NKPI natural killer/T-cell lymphoma prognostic index
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MAPKs/AP-1, and NF-κB pathways in nasopharyngeal
carcinoma [45]. The results mutually show that MAPK
and NF-κB pathways may be potentially responsible for
the LMP1-induced upregulation of PD-L1 expression in
EBV-driven malignancies.
In a retrospective cohort of 30 NKTCL patients re-
ported by Han et al., PD-L1 was aberrantly expressed in
nasal NKTCL specimens compared with the rhinitis
specimens and PD-L1 expression closely correlated with
some clinical and histopathological parameters [28].
However, the prognostic impact of PD-L1 expression in
NKTCL patients was not reported in this study. Another
finding of our study is that the levels of PD-L1 expres-
sion on tumor tissues and the concentration of serum
soluble PD-L1 correlated with survival in early-stage
NKTCL patients. For early-stage (stage I~II) NKTCL,
RT has been well established as the primary treatment
[5–7], and chemotherapy may yield additional benefits
for high-risk individuals [54]. Chemotherapies contain-
ing asparaginase (such as GELOX regimen) have pro-
duced superior response than anthracycline-based
regimens (such as CHOP or EPOCH regimen) [8–13].
In our previous study, patients with early-stage NKTCL
achieved a 3-year OS of 87.0 % after receiving GELOX
chemotherapy plus RT, which was significantly better
than that in patients receiving CHOP (54.0 %) or
EPOCH (54.0 %) plus RT [42]. In the present study,
early-stage NKTCL patients with a high concentration of
serum soluble PD-L1 or a high percentage of PD-L1
expression on tumor tissues exhibited dismal survivals
(3-year OS 45.3 and 46.5 %, respectively) even if they
were uniformly treated with asparaginase-containing
chemotherapy plus RT. Therefore, overexpression of
PD-L1 confers a negative effect on survival for early-
stage NKTCL and novel agents or treatment strategies
are warranted for this particular subgroup of patients.
Monoclonal antibodies blocking the PD-1/PD-L1 inter-
actions have exhibited promising response in several
types of lymphoma [25, 55]. There is an ongoing phase
II study evaluating the efficacy and safety of pembrolizumab
(a PD-1 antibody) in patients with relapsed/refractory
T-cell lymphomas including NKTCL (NCT02535247),
and its results may help offering another treatment
choice for this relatively rare malignancy.
Several limitations exist in this retrospective study.
The dynamic alterations of serum PD-L1 concentration
after treatment and during follow-up, as well as their
value in predicting relapse or prognosis, were not ana-
lyzed. Additionally, we did not analyze the prognostic
impact of PD-L1 among patients with advanced-stage
NKTCL due to the heterogeneous treatment delivered to
those patients. Furthermore, we were unable to examine
the levels of EBV mRNA and LMP1 expression in tumor
samples due to the limited availability of paraffin-
embedded tissues, which may provide useful information
to understand the correlation between PD-L1 expression
and EBV infection. Another issue that needs to be ad-
dressed is that the criteria of determining PD-L1 positiv-
ity varied among different studies. In Han’s study, the
product of staining intensity and percentage of positive
tumor cells was used to classify positive cases. However,
in the present and some previous studies, only the per-
centage of cells with PD-L1 staining was used due to the
heterogeneity of staining intensity, subjectivity of vi-
sional grading, and clinical feasibility [56–58]. A uniform
and widely accepted standard to determine PD-L1 posi-
tivity is required for studies in the future.
Conclusions
The present study revealed a positive correlation between
LMP1 and PD-L1 expression, which was probably mediated
by the MAPK/NF-κB pathway in NKTCL. It also showed a
significant prognostic value of PD-L1 expression level on
tumor tissues and serum soluble PD-L1 concentration in
early-stage NKTCL. Further studies are warranted to valid-
ate our findings in a prospective cohort and to explore the
therapeutic value of PD-1/PD-L1 in NKTCL.
Additional files
Additional file 1: Figure S1. PD-L1 was upregulated in SNK-6 cells
through MAPK/NF-κB pathway. (A) The expression level of p-Raf-B, Raf-B,
p-p38, p38, p-JNK, JNK, p-ERK, ERK, p65, and PD-L1 in SNK-6 cells or SNK-6
cells treated with 0.1 μM SB590885, a selective B-Raf inhibitor for 1 h. (B)
The expression level of p-ERK, ERK, p65, and PD-L1 in SNK-6 cells or SNK-
6 cells treated with 20 μM PD98059, a selective ERK inhibitor for 1 h. (C)
The expression level of p-p38, p38, p65, and PD-L1 in SNK-6 cells or SNK-
6 cells treated with 10 μM SB203580, a selective p38 inhibitor for 1 h. (D)
The expression level of p-JNK, JNK, p65, and PD-L1 in SNK-6 cells or
SNK-6 cells treated with 20 μM SP600125, a selective JNK inhibitor for 1 h.
(E) The expression level of p65 and PD-L1 in SNK-6 cells or SNK-6 cells
treated with 100 μM pyrrolidine dithiocarbamate (PDTC), a selective
inhibitor of NF-κB for 1 h. (TIF 1305 kb)
Additional file 2: Figure S2. The receiver operating curve (ROC) of (A)
pretreatment serum concentration of PD-L1 and (B) histological PD-L1
expression in tumor tissues. The optimal cut-off value for pretreatment serum
concentration of PD-L1 to predict mortality is 3.4 ng/ml (area under curve =
0.799, sensitivity = 88.9 %, specificity = 72.9 %). The optimal cut-off value for
histological PD-L1 expression in tumor tissues to predict mortality is 38 % (area
under curve = 0.760, sensitivity = 77.8 %, specificity = 79.7 %). (TIF 873 kb)
Additional file 3: Figure S3. Immunohistochemical analysis of PD-L1
expression in tumor tissues from patients with natural killer/T-cell lymphoma.
Representative images of (A) strong and (B) weak cell membrane staining
(brown) of PD-L1 are shown (×200 magnification). (TIF 7689 kb)
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